A novel conditionally replicating "armed" adenovirus selectively targeting gastrointestinal tumors with aberrant wnt signaling

Human Gene Therapy

Volumn 22, Issue 4, 2011, Pages 427-437

  Liu, Xinjian ^a,b   Qian, Qijun ^c   Xu, Ping ^b   Wolf, Frank ^d   Zhang, Jufeng ^a   Zhang, Dabing ^a   Li, Chuanyuan ^e   Huang, Qian ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b EYE AND ENT HOSPITAL OF FUDAN UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CASPASE 3; CONDITIONALLY REPLICATING ADENOVIRUS; E1A PROTEIN; INTERLEUKIN 24; WNT1 PROTEIN;

ADENOVIRUS INFECTION; APOPTOSIS; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; GENE CASSETTE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; PLASMA CLEARANCE; PROTEIN EXPRESSION; PSEUDOTYPING; SIGNAL TRANSDUCTION; STOMACH TUMOR; TRANSGENE; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; GASTROINTESTINAL NEOPLASMS; GENE ORDER; GENETIC VECTORS; HCT116 CELLS; HEK293 CELLS; HEP G2 CELLS; HUMANS; INTERLEUKINS; MICE; MICE, INBRED BALB C; MICE, NUDE; SIGNAL TRANSDUCTION; TRANSDUCTION, GENETIC; VIRUS REPLICATION; WNT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE;

EID: 79954505035     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2010.128     Document Type: Article

References (39)

1. Aberle, H., Bauer, A., Stappert, J., et al. (1997). b-Catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16, 3797-3804.
2. Biederer, C., Ries, S., Brandts, C.H., and McCormick, F. (2002). Replication-selective viruses for cancer therapy. J. Mol. Med. 80, 163-175. (Pubitemid 34230636)
3. Brunori, M., Malerba, M., Kashiwazaki, H., and Iggo, R. (2001). Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway. J. Virol. 75, 2857-2865. (Pubitemid 32185051)
4. Chen, R.H., and McCormick, F. (2001). Selective targeting to the hyperactive b-catenin/T-cell factor pathway in colon cancer cells. Cancer Res. 61, 4445-4449. (Pubitemid 32685773)
5. Chen, Z., Hagler, J., Palombella, V.J., et al. (1995). Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev. 9, 1586-1597.
6. Clevers, H. (2006). Wnt/beta-catenin signaling in development and disease. Cell 127, 469-480.
7. Coyne, C.B., and Bergelson, J.M. (2005). CAR: A virus receptor within the tight junction. Adv. Drug Deliv. Rev. 57, 869-882. (Pubitemid 40488108)
8. Crompton, A.M., and Kirn, D.H. (2007). From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr. Cancer Drug Targets 7, 133-139. (Pubitemid 46348627)
9. Cunningham, C.C., Chada, S., Merrit, J.A., et al. (2005). Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol. Ther. 11, 149-159. (Pubitemid 40012009)
10. De La Coste, A., Romagnolo, B., Billuart, P., et al. (1998). Somatic mutations of the b-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl. Acad. Sci. U.S.A. 95, 8847-8851. (Pubitemid 28350577)
11. Dihlmann, S., and von Knebel Doeberitz, M. (2005). Wnt/ b-catenin-pathway as a molecular target for future anti-cancer therapeutics. Int. J. Cancer 113, 515-524. (Pubitemid 40038726)
12. Doloff, J.C., Waxman, D.J., and Jounaidi, Y. (2008). Human tel-omerase reverse transcriptase promoter-driven oncolytic ade-novirus with E1B-19 kDa and E1B-55 kDa gene deletions. Hum. Gene Ther. 19, 1383-1400.
13. Eager, R., Harle, L., and Nemunaitis, J. (2008). Ad-MDA-7; INGN 241: a review of preclinical and clinical experience. Expert Opin. Biol. Ther. 8, 1633-1643.
14. Fisher, P.B., Gopalkrishnan, R.V., Chada, S., et al. (2003). mda-7/ IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol. Ther. 2, S23-S37.
15. Fuerer, C., and Iggo, R. (2002) Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Ther. 9, 270-281. (Pubitemid 34256902)
16. Giles, R.H., Van Es, J.H., and Clevers, H. (2003). Caught up in a Wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta 1653, 1-24. (Pubitemid 36627817)
17. Gupta, P., Su, Z.Z., Lebedeva, I.V., et al. (2006). Mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol. Ther. 111, 596-628. (Pubitemid 44118431)
18. Hardcastle, J., Kurozumi, K., Chiocca, E.A., and Kaur, B. (2007). Oncolytic viruses driven by tumor-specific promoters. Curr. Cancer Drug Targets 7, 181-189. (Pubitemid 46348633)
19. Huang, Q., Zhang, X., Wang, H., et al. (2004). A novel conditionally replicative adenovirus vector targeting telomerase-positive tumor cells. Clin. Cancer Res. 10, 1439-1445. (Pubitemid 38365239)
20. Ilyas, M., Tomlinson, I.P., Rowan, A., et al. (1997). B-Catenin mutations in cell lines established from human colorectal cancers. Proc. Natl. Acad. Sci. U.S.A. 94, 10330-10334. (Pubitemid 27407041)
21. Ji, X., Zhang, J., Cheng, L., et al. (2009). Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model. Exp. Eye Res. 89, 193-199.
22. Kim, J., Cho, J.Y., Kim, J.H., et al. (2002) Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy. Cancer Gene Ther. 9, 725-736. (Pubitemid 34971303)
23. Kim, J., Kim, P.H., Yoo, J.Y., et al. (2009). Double E1B 19 kDa-and E1B 55kDa-deleted oncolytic adenovirus in combination with radiotherapy elicits an enhanced anti-tumor effect. Gene Ther. 16, 1111-1121.
24. Lebedeva, I.V., Emdad, L., Su, Z.Z., et al. (2007). mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int. J. Oncol. 31, 985-1007.
25. Lipinski, K.S., Djeha, A.H., Ismail, T., et al. (2001). High-level, b-catenin/TCF-dependent transgene expression in secondary colorectal cancer tissue. Mol. Ther. 4, 365-371. (Pubitemid 33040522)
26. Lipinski, K.S., Djeha, A.H., Gawn, J., et al. (2004). Optimization of a synthetic beta-catenin-dependent promoter for tumor-specific cancer gene therapy. Mol. Ther. 10, 150-161. (Pubitemid 38878157)
27. Liu, T.C., Galanis, E., and Kirn, D. (2007). Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat. Clin. Pract. Oncol. 4, 101-117. (Pubitemid 46189539)
28. Liu, X., Li, J., Tian, Y., et al. (2010). Enhanced pancreatic cancer gene therapy by combination of adenoviral vector expressing c-erb-B2 (Her-2/neu)-targeted immunotoxin with a replication-competent adenovirus or etoposide. Hum. Gene Ther. 21, 157-170.
29. Luo, J., Xia, Q., Zhang, R., et al. (2008). Treatment of cancer with a novel dual-targeted conditionally replicative adenovirus armed with mda-7/IL-24 gene. Clin. Cancer Res. 14, 2450-2457. (Pubitemid 351551080)
30. Metzl, C., Mischek, D., Salmons, B., et al. (2006). Tissue- and tumor-specific targeting of murine leukemia virus-based replication-competent retroviral vectors. J. Virol. 80, 7070-7078. (Pubitemid 44025204)
31. Morin, P.J. (1999). b-Catenin signaling and cancer. Bioessays 21, 1021-1030.
32. O'Shea, C.C., Johnson, L., Bagus, B., et al. (2004). Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6, 611-623. (Pubitemid 40017704)
33. Pache, L., Venkataraman, S., Nemerow, G.R., and Reddy, V.S. (2008). Conservation of fiber structure and CD46 usage by subgroup B2 adenoviruses. Virology 375, 573-579.
34. Rahmani, M., Read, J.T., Carthy, J.M., et al. (2005). Regulation of the versican promoter by the b-catenin-T-cell factor complex in vascular smooth muscle cells. J. Biol. Chem. 280, 13019-13028.
35. Ravindranath, N.M.H., and Shuler, C. (2007). Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 103, 231-239.
36. Rubinfeld, B., Robbins, P., El-Gamil, M., et al. (1997). Stabilization of b-catenin by genetic defects in melanoma cell lines. Science 275, 1790-1792. (Pubitemid 27136716)
37. Vermeulen, L., De Sousa E Melo, F., Van der Heijden, M., et al. (2010). Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 12, 468-476.
38. Wong, C.M., Fan, S.T., and Ng, I.O. (2001). b-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer 92, 136-145. (Pubitemid 32623050)
39. Yost, C., Torres, M., Miller, J.R., et al. (1996). The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev. 10, 1443-1454. (Pubitemid 26260702)